Figure 3.

ARR, key MRI measures, and volumetric brain changes at last assessment in PREFERMS.

Bars show mean (SD) except in (a), where they represent mean (95% Cl), with values listed below each graph together with n for each group. Statistics in (a)–(e): negative binomial regression adjusted for treatment, number of relapses in previous 2 years, screening Expanded Disability Status Scale score, and treatment naïvety, using duration (years) as an offset variable. Statistics in (f)–(h) performed on annualized rates with a rank analysis of covariance, adjusted for treatment, treatment naïvety, corresponding baseline values, and age. All data from last assessment. **p < 0.01; ***p < 0.001; ****p < 0.0001 versus iDMTs. ARR, annualized relapse rate; CI, confidence interval; Gd+, gadolinium enhanced; iDMT, injectable disease-modifying therapy; MRI, magnetic resonance imaging; PREFERMS, Prospective, Randomized, active-controlled, open-label study to Evaluate patient retention on Fingolimod versus approved first-line disease modifying thErapies in adults with Relapsing remitting Multiple Sclerosis; SD, standard deviation.